The city of Minneapolis, Minnesota, currently has 26 active clinical trials seeking participants for Diabetes research studies.
Afrezza® INHALE-1 Study in Pediatrics
Recruiting
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine in combination with a basal insulin (i.e., the Rapid-acting Insulin Analog [RAA] injection group) in pediatric subjects with type 1 or type 2 diabetes mellitus. Following 26 weeks of randomized treatment (i.e., Afrezza or RAA injection combined with a basal insulin), all... Read More
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
02/22/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: Care Access Research - Minneapolis, Minneapolis, Minnesota
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
Recruiting
The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS). Participants will be asked to: Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2024
Locations: International Diabetes Center - HealthPartners Institute, Minneapolis, Minnesota
Conditions: Type1diabetes
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
02/14/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Diabetes Mellitus, Type 1
Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics
Recruiting
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to o... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
02/12/2024
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Osteomyelitis, Diabetes, Amputation
Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness
Recruiting
This single-arm trial of the Cardiovascular Risk Reduction Among People Experiencing Homelessness (CV-Homes) intervention alone (n=8) will test the perception and feasibility of anticipated study procedures.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Hennepin Healthcare Research Institute, Minneapolis, Minnesota
Conditions: Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension, Hyperlipidemias
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/11/2024
Locations: International Diabetes Center, Minneapolis, Minnesota
Conditions: Type 2 Diabetes
FAM (Follower, Action Plan, and Remote Monitoring) Intervention to Reduce Severe Hyperglycemia in Adults With Type 1 Diabetes Mellitus at Risk for Diabetic Ketoacidosis
Recruiting
Diabetic ketoacidosis (DKA) results in significant morbidity and healthcare utilization and is the main contributor to loss of life expectancy in people with diabetes mellitus type 1 (T1DM) <50 years old. This suggests the need to develop interventions to reduce DKA events. Innovative features of newer continuous glucose monitoring devices offer opportunities for novel strategies to reduce DKA. Designating a family member, friend, or caregiver as a Follower was associated with reduction in HbA1C... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/09/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Type 1 Diabetes
Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis
Recruiting
Randomized pilot trial of patients (n=30) undergoing Total Pancreatectomy and Islet AutoTransplant (TPIAT). Patients with islet harvest of greater than 5000 islet equivalents/kg body weight will be randomized to receive a portion of their islets into an omental pouch. For outcomes related to islet function, a group of normal volunteers (n=15) will be studied as a comparator group.
Gender:
All
Ages:
Between 18 years and 68 years
Trial Updated:
02/06/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Chronic Pancreatitis, Diabetes Mellitus, Islet Cell Transplantation
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
Recruiting
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/03/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Dail... Read More
Gender:
All
Ages:
Between 2 years and 80 years
Trial Updated:
01/18/2024
Locations: Initernational Diabetes Center, Minneapolis, Minnesota +1 locations
Conditions: Type 1 Diabetes
Diabetes in African Youth
Recruiting
This RCT aims to improve T1D care in East African children and young adults by testing the hypothesis that enabling patients to continuously monitor glucose levels with flash CGM technology will improve glucose time-in-range (glucose level 70-180 mg/dl). A second primary endpoint is to perform a cost analysis on flash glucose monitoring compared to 3x/day SMBG, to determine whether this technology is cost-effective in the setting of a less-resourced nation. After a 2 week assessment with blinde... Read More
Gender:
All
Ages:
Between 4 years and 26 years
Trial Updated:
12/28/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: type1diabetes